Literature DB >> 21875782

American College of Radiology Appropriateness Criteria(®)--locally advanced (high-risk) prostate cancer.

J P Ciezki1, I-C J Hsu, M Abdel-Wahab, V E Arterbery, S J Frank, J L Mohler, B J Moran, S A Rosenthal, C J Rossi, Y Yamada, G Merrick.   

Abstract

The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. This review focuses on locally advanced prostate cancer and the evidence for treatment outcomes, both toxicity and efficacy, across the three major treatment modalities of external beam radiotherapy, brachytherapy and surgery. Only data that could pass contemporary quality metrics were used to form this report. This body of literature suffers from an absence of trials prospectively comparing therapies for efficacy and a lack of long-term prospective comparisons of toxicity. Upon review of these data, the authors concluded that there are several acceptable methods for the treatment of locally advanced prostate cancer that is highly dependent of the patient's clinical (both prostate cancer-specific and comorbidity-specific) parameters at diagnosis.
Copyright © 2011 American College of Radiology. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21875782     DOI: 10.1016/j.clon.2011.08.003

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  2 in total

1.  Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.

Authors:  Takashi Mizowaki; Yoshiki Norihisa; Kenji Takayama; Itaru Ikeda; Haruo Inokuchi; Kiyonao Nakamura; Tomomi Kamba; Takahiro Inoue; Toshiyuki Kamoto; Osamu Ogawa; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2015-07-04       Impact factor: 3.402

Review 2.  Locally advanced prostate cancer: optimal therapy in older patients.

Authors:  Michael Froehner; Manfred P Wirth
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.